Back to list

Owkin

Developer of machine learning tools designed to augment medical and biological research.
Developer of machine learning tools designed to augment medical and biological research.
Discovery Tools (Healthcare) 📍 Paris, France Founded 2016
Current Valuation
$1.3B
as of 2021-Q4
UNICORN

QL Price

$1.1B
-13% vs last round
QuantLogix's current estimate for Owkin, published 2026-09-12 — below the last disclosed round of $1.3B (2021-Q4).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round $1.3B 2021-Q4 weight 0.04
Secondary market print $1.1B 2026-06-27 weight 0.63
How this price has held up
No round has priced for Owkin since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-12 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to Owkin →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Owkin, 2026-09-12 (14bf30945ea97f3b). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is Owkin going public?
No. Owkin is private and has not filed to go public. There is no S-1 on file.
What is Owkin's valuation in 2026?
Owkin is valued at $1.3B as of 2021-Q4, set by its Series B ($180M, Nov 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Owkin filed an S-1?
No public S-1 is on file for Owkin.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

Founded
2016
HQ
Paris, France
Employees
325
Total Raised
$254.1M
Last Round
Series B — $180M (Nov 2021)
IPO Status
private

Fundraising Status

Series B · $180M · 4y 10mo ago
privateTotal raised $254.1M

Secondary Market

Implied price / share
$36.88
Last round price / share
$43.04
vs last round
-14.3%
Last round price vs secondary price
Last round vs current secondary price per share$43.04Last round$36.88Current
Secondary price return by period
Secondary market period returns3-month0.0%6-month0.0%1-year0.0%All-time-21.5%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series B$180MNov 2021$1.3B

Vertical Intelligence — Biotech / Gene Therapy

Registered trials
1
1 active · 1 recruiting
Focus areas
Diffuse Large B Cell Lymphoma
Solid Tumor Cancer
Latest trial start
2023-05-08
Name-verified against lead sponsor "OWKIN" on ClinicalTrials.gov as of 2026-09-11. Verify on ClinicalTrials.gov ↗

Talent Signal

Hiring trend
First snapshot
trend accrues with monthly sweeps
Open roles
6
via ashby
Product-build share
67%
engineering, research, product, design
Trajectory
steady
heavy product build — 67% of open roles are product-building functions (engineering/research/product) — 2 of 6 open roles are other.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by month6Aug '26
Open roles by function
Open roles by functionOther2Engineering2Research1Data & ML1
product-building   go-to-market / G&A
Senior Software Engineer (Platform)Senior AI ScientistSoftware EngineerSoftware Engineering / Machine Learning Engineering InternDirector, Biopharma Data ScienceTeam Lead, Platform Services
Counted from Owkin's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Artificial IntelligenceBiotechnologyClinical TrialsMachine LearningPharmaceutical
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q4. Refreshed quarterly.